Casdatifan, an oral investigational therapy designed to inhibit hypoxia-inducible factor-2 alpha, produced durable tumor responses with a manageable safety profile in patients with heavily pretreated clear cell renal cell carcinoma, according to the ARC-20 phase 1 clinical trial.
Elevated calcium levels in the blood—a complication of kidney cancers known as hypercalcemia—may be successfully treated with HIF-2α inhibitors developed by UT Southwestern Medical Center.
